exRNAdisease

Entry Detail

---



General Information

Database ID: exR0087990 RNA Name: hsa-miR-299-3p RNA Type: miRNA Chromosome: chr14 Starnd: + Coordinate: Start Site(bp): 101023832 End Site(bp): 101023853 External Links: hsa-miR-299-3p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand AFF4 chr5 132875395 132963634 - AK2 chr1 33007940 33080996 - AP3M1 chr10 74120255 74151063 - ARCN1 chr11 118572390 118603033 + CASP2 chr7 143288215 143307696 + CMIP chr16 81445170 81711762 + COL4A2 chr13 110305812 110513209 + CORO2B chr15 68578993 68727806 + DHX33 chr17 5440917 5468982 - DNAJC9 chr10 73183362 73247255 - E2F6 chr2 11444375 11466177 - FHL2 chr2 105357712 105438513 - GLCCI1 chr7 7968796 8094272 + LY6E chr8 143017982 143023832 + MAP3K14 chr17 45263119 45317029 - MAP3K2 chr2 127298730 127388465 - MAP3K20 chr2 173075435 173268015 + MBNL1 chr3 152243828 152465780 + MPZL1 chr1 167721192 167791919 + PCGF3 chr4 705748 770640 + PGK1 chrX 77910739 78129295 + PTPRJ chr11 47980558 48170841 + RAB8A chr19 16111889 16134234 + SAMD4B chr19 39342396 39385710 + SORBS3 chr8 22544986 22575788 + TCF3 chr19 1609290 1652615 - TMEM127 chr2 96248516 96265994 - USP37 chr2 218450251 218568351 - ZIC1 chr3 147393422 147510293 + miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0001349 chr3 152132729 152150709 + hsa_circ_0001605 chr6 42903447 42905047 + hsa_circ_0001146 chr20 34241449 34246936 - lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC016876.2 chr17 7581964 7584086 - AC135048.1 chr16 30948386 30956511 + DSCAM-AS1 chr21 40383083 40385358 + KCNQ1OT1 chr11 2608328 2699994 - NEAT1 chr11 65422774 65445540 + TUG1 chr22 30969245 30979395 + Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.